FIELD: medicine.
SUBSTANCE: allelic variants of TPMT gene and MUTYH gene polymorphisms rs1142345 and rs3219484 are determined in a patient; the allelic status of one or both of the above polymorphisms provides predicting the cisplatin treatment efficacy, wherein the favourable prognosis is stated by the presence two polymorphic wild-type alleles rs1142345 of TPMT gene (genotype AA) and/or a combination of polymorphic wild-and mutant-type alleles rs3219484 of MUTYH gene (genotype GA).
EFFECT: implementing the invention is expected to identify the variations which can provide a basis to individualise the use of platinum preparations in an anti-tumour therapy.
3 cl, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ASSESSING PRIMARY RESPONSE TO COMBINED CHEMOTHERAPY OF SPORADIC OVARIAN CANCER OF STAGES III AND IV | 2021 |
|
RU2769543C2 |
| METHOD FOR DETECTION OF SURROGATE MARKERS OF MUTATIONS OF GENES OF VARIABLE REGIONS OF HEAVY CHAINS OF IMMUNOGLOBULINS IN CHRONIC LYMPHOCYTIC LEUKEMIA | 2023 |
|
RU2824086C1 |
| IMPROVED METHOD AND KIT FOR DETERMINING SEVERITY AND PROGRESSION LEVEL OF PERIODONTAL DISEASE | 2011 |
|
RU2664431C2 |
| GENETIC POLYMORPHISMS ACCOMPANYING AGE-RELATED MACULAR DEGENERATION | 2010 |
|
RU2546008C2 |
| GENETIC POLYMORPHISMS IN AGE-RELATED MACULAR DEGENERATION | 2010 |
|
RU2577726C2 |
| METHOD FOR PREDICTING THE RISK OF DEVELOPING COVID-19 IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES | 2022 |
|
RU2783422C1 |
| METHOD FOR ASSESSING THE RISK OF SEVERE ACNE BASED ON DETERMINING THE EXPRESSION OF IL1RN AND IL10 GENES | 2020 |
|
RU2739890C1 |
| METHOD FOR IDENTIFICATION OF GENETIC POLYMORPHISMS AFFECTING METABOLISM OF ANTICANCER DRUGS USING BIOLOGICAL MICROCHIPS | 2018 |
|
RU2697096C1 |
| VEGF POLYMORPHISM AND ANTIANGIOGENESIS THERAPY | 2008 |
|
RU2482491C2 |
| VEGF POLYMORPHISM AND ANTIANGIOGENESIS THERAPY | 2013 |
|
RU2635525C2 |
